Mathew Krista, MD
Emergency Medicine · Dothan, ALNPI 1093779738
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $569, 4.9 times the $115 reported in 2019. Among emergency medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 146 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$424
- AbbVie$347
- Lilly USA, LLC$289
- Merck$219
- Pfizer$171
- Bayer$123
- plus $805 from 24 others
What the payments were for
- Food & beverage$2,378100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $424 |
| AbbVie | 24 | $347 |
| Lilly USA, LLC | 22 | $289 |
| Merck | 15 | $219 |
| Pfizer | 10 | $171 |
| Bayer | 5 | $123 |
| Eisai Inc. | 5 | $72 |
| Nevro Corp. | 3 | $64 |
| Johnson & Johnson | 4 | $64 |
| Biohaven Pharmaceuticals, Inc. | 3 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $54 |
| Novartis | 3 | $53 |
| Novo Nordisk | 3 | $47 |
| GSK | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Dexcom, Inc. | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $26 |
| Idorsia Pharmaceuticals US Inc | 2 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $24 |
| Amgen | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Shield Therapeutics Inc | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Exact Sciences | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$2,378 in reported general payments places this provider in the 95th percentile of 565 emergency medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 151 | $1,543 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $1,096 |
| Cefdinir | 53 | $1,061 |
| Fluticasone Propionate | 81 | $939 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 60 | $631 |
| Methylprednisolone | 61 | $530 |
| Ciprofloxacin Hcl | 60 | $520 |
| Levocetirizine Dihydrochloride | 66 | $481 |
| Cephalexin | 39 | $354 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 66 | $345 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 17 | $338 |
| Azithromycin | 70 | $249 |
| Mupirocin | 30 | $229 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 33 | $220 |
| Tizanidine Hcl | 27 | $209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPaxlovid | $171 | $028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 emergency medicine providers in Alabama.
Other emergency medicine in Dothan
- John McDonaldDothan$1K
- Mark MitchellAtmore$309K
- James GalbraithBirmingham$74K
- Lauren WalterBirmingham$64K
- Mark ChristensenBoaz$31K
- Lisa Moreno-WaltonMobile$23K
- Jeremy TownsPell City$10K
- Malika AryanpureNorthport$9K
- Jorge AlsipMobile$8K
- Brian HassaniMontgomery$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.